Identifying ERC2-IT1 (Po42) as A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: ERC2-IT1

NCBI ID: G711

ERC2-IT1

Other Name(s): Po42 | ERC2 intronic transcript 1 | C3orf51 | C1orf1

Identifying ERC2-IT1 (Po42) as A Potential Drug Target and Biomarker for Neurodegenerative Diseases

ERC2-IT1 (Po42) is a protein that is expressed in the endoplasmic reticulum (ER) and is involved in the transport of various molecules, including small molecules, peptides, and proteins. It is a key protein for the intracellular transport system, which is responsible for moving molecules from the cytoplasm to the ER and other intracellular structures.

Research has identified ERC2-IT1 (Po42) as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and neurological disorders. This is because the disruptions in ERC2-IT1 (Po42) expression have been observed to be associated with the development and progression of these diseases.

One of the reasons why ERC2-IT1 (Po42) has been identified as a potential drug target is its role in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells, which can lead to a range of symptoms, including cognitive decline, tremors, and difficulty with daily living.

Studies have shown that ERC2-IT1 (Po42) is expressed in the brains of individuals with Alzheimer's disease and that its expression is correlated with the severity of the disease. Additionally, several studies have shown that inhibiting ERC2-IT1 (Po42) can protect against the neurotoxicity of various neurodegenerative drugs, suggesting that it may be a useful target for these conditions.

ERC2-IT1 (Po42) has also been identified as a potential biomarker for neurodegenerative diseases. The loss of ERC2-IT1 (Po42) has been observed in the brains of individuals with neurodegenerative conditions, and these losses are associated with the severity of the disease. This suggests that ERC2-IT1 (Po42) may be a useful biomarker for neurodegenerative diseases.

In addition to its potential role as a drug target and biomarker, ERC2-IT1 (Po42) is also of interest as a potential therapeutic target for other conditions. For example, ERC2-IT1 (Po42) has been shown to be involved in the regulation of cellular processes that are important for the development and maintenance of cancer.

Studies have shown that ERC2-IT1 (Po42) is expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, several studies have shown that inhibiting ERC2-IT1 (Po42) can inhibit the growth and metastasis of cancer cells, suggesting that it may be a useful target for cancer treatment.

ERC2-IT1 (Po42) has also been identified as a potential target for other conditions, including neurological disorders and autoimmune diseases. For example, studies have shown that ERC2-IT1 (Po42) is involved in the regulation of the immune response and that its dysfunction may be a cause of various neurological disorders, including multiple sclerosis and autoimmune diseases.

In conclusion, ERC2-IT1 (Po42) is a protein that is expressed in the endoplasmic reticulum and is involved in the intracellular transport system. Its role in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, makes it a potential drug target. Additionally, its potential as a biomarker for neurodegenerative diseases and its involvement in the regulation of cellular processes that are important for cancer development and progression make it a

Protein Name: ERC2 Intronic Transcript 1

The "ERC2-IT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERC2-IT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets